Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10159666 Dosing of cabozantinib formulations

Patent 10159666 was granted and assigned to Exelixis Ltd on December, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Exelixis Ltd
Date Filed
March 17, 2015
Date of Patent
December 25, 2018
Patent Applicant
Exelixis
Exelixis
Patent Application Number
15126767
Patent Citations Received
‌
US Patent 12064430 Kinase inhibitor salts and compositions thereof
0
‌
US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
‌
US Patent 11065240 Drug combinations to treat multiple myeloma
‌
US Patent 11760726 Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
‌
US Patent 10501418 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
‌
US Patent 11564915 Cabozantinib dosage form and use in the treatment of cancer
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10159666
Patent Primary Examiner
‌
Taofiq A. Solola

Find more entities like US Patent 10159666 Dosing of cabozantinib formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo